PCK
vs
S
S&P/ASX 300
PCK
Over the past 12 months, PCK has underperformed S&P/ASX 300, delivering a return of -48% compared to the S&P/ASX 300's +12% growth.
Stocks Performance
PCK vs S&P/ASX 300
Performance Gap
PCK vs S&P/ASX 300
Performance By Year
PCK vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
PainChek Ltd
Glance View
PainChek Ltd. engages in the development and commercialisation of mobile medical device applications. The company is headquartered in Sydney, New South Wales. The company went IPO on 2012-05-01. The Company’s principal activities are development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate their pain with carers. Its Paincheck is an Adult and Infant pain assessment applications. Its PainChek technology uses cameras in smartphones and tablets to capture a brief video of the person, which is analyzed in real time using facial recognition software to detect the presence of facial micro-expressions that are indicative of the presence of pain. Its Paincheck uses artificial intelligence (AI) to automatically assess the micro-facial features of pain. Its PainChek technology has multiple regulatory clearances, including TGA (Australia) and CE Mark (Europe) for use as a class 1 medical device to assess pain in people who are unable to reliably verbalize, such people with dementia.
